Cardiovascular Pharmacogenetics

¡ Handbook of Experimental Pharmacology āĻ•āĻŋāϤāĻžāĻĒ 160 ¡ Springer Science & Business Media
ā§Ģ.ā§Ļ
ā§§ āϟāĻž āĻĒā§°ā§āϝāĻžāϞ⧋āϚāύāĻž
āχāĻŦ⧁āĻ•
407
āĻĒ⧃āĻˇā§āĻ āĻž
āĻŽā§‚āĻ˛ā§āϝāĻžāĻ‚āĻ•āύ āφ⧰⧁ āĻĒā§°ā§āϝāĻžāϞ⧋āϚāύāĻž āϏāĻ¤ā§āϝāĻžāĻĒāύ āϕ⧰āĻž āĻšā§‹ā§ąāĻž āύāĻžāχ  āĻ…āϧāĻŋāĻ• āϜāĻžāύāĻ•

āĻāχ āχāĻŦ⧁āĻ•āĻ–āύ⧰ āĻŦāĻŋāĻˇā§Ÿā§‡

The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

āĻŽā§‚āĻ˛ā§āϝāĻžāĻ‚āĻ•āύ āφ⧰⧁ āĻĒā§°ā§āϝāĻžāϞ⧋āϚāύāĻžāϏāĻŽā§‚āĻš

ā§Ģ.ā§Ļ
ā§§ āϟāĻž āĻĒā§°ā§āϝāĻžāϞ⧋āϚāύāĻž

āĻāχ āχāĻŦ⧁āĻ•āĻ–āύāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžāĻ‚āĻ•āύ āϕ⧰āĻ•

āφāĻŽāĻžāĻ• āφāĻĒā§‹āύāĻžā§° āĻŽāϤāĻžāĻŽāϤ āϜāύāĻžāĻ“āĻ•āĨ¤

āĻĒāĻĸāĻŧāĻžā§° āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻžā§ąāϞ⧀

āĻ¸ā§āĻŽāĻžā§°ā§āϟāĻĢ’āύ āφ⧰⧁ āĻŸā§‡āĻŦāϞ⧇āϟ
Android āφ⧰⧁ iPad/iPhoneā§° āĻŦāĻžāĻŦ⧇ Google Play Books āĻāĻĒāĻŸā§‹ āχāύāĻˇā§āϟāϞ āϕ⧰āĻ•āĨ¤ āχ āĻ¸ā§āĻŦāϝāĻŧāĻ‚āĻ•ā§āϰāĻŋāϝāĻŧāĻ­āĻžā§ąā§‡ āφāĻĒā§‹āύāĻžā§° āĻāĻ•āĻžāωāĻŖā§āϟ⧰ āϏ⧈āϤ⧇ āĻ›āĻŋāĻ‚āĻ• āĻšāϝāĻŧ āφ⧰⧁ āφāĻĒ⧁āύāĻŋ āϝ'āϤ⧇ āύāĻžāĻĨāĻžāĻ•āĻ• āϤ'āϤ⧇āχ āϕ⧋āύ⧋ āĻ…āĻĄāĻŋāĻ…'āĻŦ⧁āĻ• āĻ…āύāϞāĻžāχāύ āĻŦāĻž āĻ…āĻĢāϞāĻžāχāύāϤ āĻļ⧁āύāĻŋāĻŦāϞ⧈ āϏ⧁āĻŦāĻŋāϧāĻž āĻĻāĻŋāϝāĻŧ⧇āĨ¤
āϞ⧇āĻĒāϟāĻĒ āφ⧰⧁ āĻ•āĻŽā§āĻĒāĻŋāωāϟāĻžā§°
āφāĻĒ⧁āύāĻŋ āĻ•āĻŽā§āĻĒāĻŋāωāϟāĻžā§°ā§° ā§ąā§‡āĻŦ āĻŦā§āϰāĻžāωāϜāĻžā§° āĻŦā§āĻ¯ā§ąāĻšāĻžā§° āϕ⧰āĻŋ Google PlayāϤ āĻ•āĻŋāύāĻž āĻ…āĻĄāĻŋāĻ…'āĻŦ⧁āĻ•āϏāĻŽā§‚āĻš āĻļ⧁āύāĻŋāĻŦ āĻĒāĻžā§°ā§‡āĨ¤
āχ-ā§°ā§€āĻĄāĻžā§° āφ⧰⧁ āĻ…āĻ¨ā§āϝ āĻĄāĻŋāĻ­āĻžāχāϚ
Kobo eReadersā§° āĻĻ⧰⧇ āχ-āϚāĻŋ⧟āĻžāρāĻšā§€ā§° āĻĄāĻŋāĻ­āĻžāχāϚāϏāĻŽā§‚āĻšāϤ āĻĒā§āĻŋāĻŦāϞ⧈, āφāĻĒ⧁āύāĻŋ āĻāϟāĻž āĻĢāĻžāχāϞ āĻĄāĻžāωāύāĻ˛â€™āĻĄ āϕ⧰āĻŋ āϏ⧇āχāĻŸā§‹ āφāĻĒā§‹āύāĻžā§° āĻĄāĻŋāĻ­āĻžāχāϚāϞ⧈ āĻ¸ā§āĻĨāĻžāύāĻžāĻ¨ā§āϤ⧰āĻŖ āϕ⧰āĻŋāĻŦ āϞāĻžāĻ—āĻŋāĻŦāĨ¤ āϏāĻŽā§°ā§āĻĨāĻŋāϤ āχ-ā§°āĻŋāĻĄāĻžā§°āϞ⧈ āĻĢāĻžāχāϞāĻŸā§‹ āϕ⧇āύ⧇āĻ•ā§ˆ āĻ¸ā§āĻĨāĻžāύāĻžāĻ¨ā§āϤ⧰ āϕ⧰āĻŋāĻŦ āϜāĻžāύāĻŋāĻŦāϞ⧈ āϏāĻšāĻžāϝāĻŧ āϕ⧇āĻ¨ā§āĻĻā§ā§°āϤ āĻĨāĻ•āĻž āϏāĻŦāĻŋāĻļ⧇āώ āύāĻŋā§°ā§āĻĻ⧇āĻļāĻžā§ąāϞ⧀ āϚāĻžāĻ“āĻ•āĨ¤